Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial.

David Staskin,Jeffrey Frankel,Susann Varano,Michael Kennelly,Diane K Newman,Matt T Rosenberg,Denise D Shortino,Rachael A Jankowich,Paul N Mudd

International journal of clinical practice（2022）

引用 2|浏览9

暂无评分

摘要

In this subgroup analysis from the EMPOWUR trial, vibegron was associated with significant reductions compared with placebo in urgency episodes and micturitions in both the OAB dry and wet populations, suggesting that vibegron is similarly efficacious for these endpoints in patients with and without UUI. This trial is registered with NCT03492281.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要